Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD3 | Q9BZ95 | 2/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.51 |
| ▸ | AHCY | P23526 | 2/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PI4KA | P42356 | 4/20 | 0.45 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.45 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.45 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.45 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14955424 | 1.00 | NSD3 (0.52) | NSD3ADORA2AAHCYADORA1ALDH1A1 | |
| SCHEMBL29249897 | 0.87 | NSD3 (0.53) | NSD3ADORA2AAHCYADORA1ALDH1A1 | |
| SCHEMBL29249895 | 0.87 | NSD3 (0.53) | NSD3ADORA2AAHCYADORA1ALDH1A1 | |
| SCHEMBL2563455 | 0.83 | CTSK (0.47) | NSD3ADORA2AAHCYHPGDSMN1; SMN2 | |
| SCHEMBL2563452 | 0.83 | CTSK (0.47) | NSD3ADORA2AAHCYHPGDSMN1; SMN2 | |
| SCHEMBL2563457 | 0.83 | CTSK (0.47) | NSD3ADORA2AAHCYHPGDSMN1; SMN2 | |
| SCHEMBL2575266 | 0.81 | HPRT1 (0.57) | ALDH1A1LMNASMN1; SMN2CYP3A4 | |
| SCHEMBL2575270 | 0.81 | HPRT1 (0.57) | ALDH1A1LMNASMN1; SMN2CYP3A4 | |
| SCHEMBL14955846 | 0.80 | MGMT (0.42) | ADORA2AADORA1ALDH1A1HPGDLMNA | |
| SCHEMBL14955845 | 0.80 | MGMT (0.42) | ADORA2AADORA1ALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087219-A1 | OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS | ALNYLAM PHARMACEUTICALS INC (US) | 2021-03-25 | — | — | US | disclosed |
| US-10913767-B2 | Oligonucleotides comprising acyclic and abasic nucleosides and analogs | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20130130378-A1 | OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2011133876-A2 | OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913767-B2 | Oligonucleotides comprising acyclic and abasic nucleosides and analogs | NSUN2, BCDIN3D, ADAR | NSD3 1377/4885ADORA2A 660/4885AHCY 1111/4885 |
| US-20130130378-A1 | OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS | ADAR, TYMS, POLM | NSD3 1273/4885ADORA2A 169/4885AHCY 510/4885 |
| US-20210087219-A1 | OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS | NSUN2, BCDIN3D, RNGTT | NSD3 1568/4885ADORA2A 632/4885AHCY 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.